TY - JOUR
T1 - Transcatheter aortic valve implantation
T2 - Current status and future perspectives
AU - Cahill, T. J.
AU - Chen, M.
AU - Hayashida, K.
AU - Latib, A.
AU - Modine, T.
AU - Piazza, N.
AU - Redwood, S.
AU - Søndergaard, L.
AU - Prendergast, B. D.
N1 - Publisher Copyright:
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018.
PY - 2018/7/21
Y1 - 2018/7/21
N2 - In the 16 years since the first pioneering procedure, transcatheter aortic valve implantation (TAVI) has come of age and become a routine strategy for aortic valve replacement, increasingly performed under conscious sedation via transfemoral access. Simplification of the procedure, accumulation of clinical experience, and improvements in valve design and delivery systems have led to a dramatic reduction in complication rates. These advances have allowed transition to lower risk populations, and outcome data from the PARTNER 2A and SURTAVI trials have established a clear evidence base for use in intermediate risk patients. Ongoing studies with an expanding portfolio of devices seem destined to expand indications for TAVI towards lower risk, younger and asymptomatic populations. In this article, we outline recent advances, new devices and current guidelines informing the use of TAVI, and describe remaining uncertainties that need to be addressed.
AB - In the 16 years since the first pioneering procedure, transcatheter aortic valve implantation (TAVI) has come of age and become a routine strategy for aortic valve replacement, increasingly performed under conscious sedation via transfemoral access. Simplification of the procedure, accumulation of clinical experience, and improvements in valve design and delivery systems have led to a dramatic reduction in complication rates. These advances have allowed transition to lower risk populations, and outcome data from the PARTNER 2A and SURTAVI trials have established a clear evidence base for use in intermediate risk patients. Ongoing studies with an expanding portfolio of devices seem destined to expand indications for TAVI towards lower risk, younger and asymptomatic populations. In this article, we outline recent advances, new devices and current guidelines informing the use of TAVI, and describe remaining uncertainties that need to be addressed.
KW - Aortic stenosis
KW - Aortic valve replacement
KW - Computed tomography
KW - TAVI
KW - TAVR
KW - Transcatheter aortic valve implantation
KW - Transcatheter aortic valve replacement
UR - http://www.scopus.com/inward/record.url?scp=85050139647&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050139647&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehy244
DO - 10.1093/eurheartj/ehy244
M3 - Review article
C2 - 29718148
AN - SCOPUS:85050139647
SN - 0195-668X
VL - 39
SP - 2625
EP - 2634
JO - European heart journal
JF - European heart journal
IS - 28
ER -